Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cost-Effectiveness of Transfusion of Platelet Components Prepared with Pathogen Inactivation Treatment in the United States

Christopher F. Bell, MS, Marc F. Botteman, MS, Xin Gao, PhD, Joel L. Weissfeld, MD, Maarten J. Postma, PhD, Chris L. Pashos, PhD, Darrell Triulzi, MD, and Ulf Staginnus, MS

1Abt Associates Inc., Health Economic Research and Quality of Life Evaluation Services (HERQuLES), Bethesda, Maryland, 2University of Pittsburgh, Pittsburgh, Pennsylvania, 3Groningen University Institute for Drug Exploration/Groningen Research Institute of Pharmacy, University Groningen, Groningen, the Netherlands, 4Abt Associates Inc., HERQuLES, Cambridge, Massachusetts, and 5Baxter Healthcare Corporation, SL, Transfusion Therapies, Madrid, Spain

ABSTRACT

Background: The Intercept Blood System (IBS) for platelets has been developed to reduce pathogen transmission risks during transfusions.

Objective: This study was a comprehensive economic analysis of the cost-effectiveness of using the IBS for single-donor apheresis platelets (AP) and random-donor pooled platelet concentrates (PC) versus AP and PC without the IBS in the United States in patient populations in which platelets are commonly transfused.

Methods: All data used in this analysis were summarized from existing published sources (primarily indexed in MEDLINE) and data on file at Baxter Healthcare Corporation (Chicago, Illinois) and Cerus Corporation (Concord, California). A literature-based decision-analytic model was developed to assess the economic costs and clinical outcomes associated with the use of AP and PC treated with the IBS for several conditions and procedures that account for a considerable proportion of the platelet usage in the United States: acute lymphocytic leukemia, non-Hodgkin's lymphoma, coronary artery bypass graft, and hip arthroplasty. Risks of infection with HIV, hepatitis C virus (HCV), hepatitis B virus, human T-cell lymphotropic virus type 1, or bacterial agents were incorporated into the model. Possible benefits of reduction of the risk of emerging HCV-like pathogens and elimination of the need for gamma irradiation were explored in sensitivity analyses.

Results: The incremental cost per quality-adjusted life-year gained by using AP + IBS versus untreated AP ranged from $1,308,833 to $4,451,650 (without bacte-
Conclusions: The cost-effectiveness of pathogen inactivation via the IBS for platelets is comparable to that of other accepted blood safety interventions (eg, nucleic acid amplification technology). The IBS for platelets may be considered a desirable strategy to increase the safety of platelet transfusions and a potential insurance against the threat of emerging pathogens. (Clin Ther. 2003;25:2464–2486) Copyright © 2003 Excerpta Medica, Inc.

Key words: pathogen inactivation, transfusion risks, cost-effectiveness, platelet.

INTRODUCTION
The safety of blood transfusions has been a major concern of health care policymakers, especially when faced with the risk of transmission of infectious blood-borne pathogens such as HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), human T-cell lymphotropic virus type 1 (HTLV-1), and bacteria.1 Measures to reduce transfusion-transmission risks include donor screening/education strategies, laboratory testing (eg, nucleic acid amplification technology [NAT], HIV p24 antigen test), preoperative autologous donation, limitation of donor exposure by use of single-donor apheresis platelets (AP), and leukocyte reduction.

The benefits of these measures have been realized in the form of a reduction in the risk of transmission of infectious pathogens.1 However, these measures have limitations, and there remains a residual risk attributable to window-period donations.2-4 For instance, the residual risk of transmission has been estimated at 1 per 734,000 to 2,135,000 units for HIV and 1 per 138,000 to 1,935,000 units for HCV, depending on donor status.3

Perhaps of greater concern is the challenge of protection of blood components, particularly platelets, from bacterial contamination.5 Platelets, which are stored at room temperature, offer a nutrient-rich environment in which bacteria can multiply. Although laboratory tests to detect bacterial contamination of platelets exist, they are not routinely performed. The overall incidence of transfusion-related sepsis (TRS) due to bacterial contamination of platelets is relatively high: in 3
recent surveillance studies, the death rates due to bacterial contamination of platelets were reported to range from 2 to 15 per million units with AP and 2 to 62 per million units with random-donor pooled platelet concentrates (PC).6-8

Pathogen inactivation treatment with the Intercept Blood System* (IBS) for platelets is a new technology aimed at enhancing the safety of platelet transfusions. The IBS inactivates a broad spectrum of viruses, bacteria, and parasites present in platelet components by targeting the DNA and RNA in the pathogen and forming irreversible crosslinks, thus preventing pathogen replication.9-11 The process is effective against pathogens but does not affect in vitro and in vivo platelets that do not require genetic material to function. Use of treated platelets may substantially reduce both the risk of pathogen transmission and the risk of TRS due to bacterial contamination. Furthermore, use of platelets processed with a pathogen inactivation treatment may protect future platelet recipients from emerging pathogens for which donor screening may be ineffective or for which there are no tests. Because of concomitant use of other blood products, such as red blood cells and plasma (which are often administered with platelets), transfusion risks are not entirely eliminated. However, ongoing advanced clinical trials12,13 are investigating pathogen inactivation treatment of red blood cells11 and plasma.12

When faced with the decision of whether to adopt new treatment strategies such as the IBS, health care policy makers must balance the competing interests of public safety and efficient use of health care resources. Although an improvement in the overall safety of platelet transfusions may result from the use of the IBS for platelets, the benefits of such a system presumably would be achieved at an extra cost. Cost-effectiveness analysis—assessing the net changes in costs and outcomes of medical interventions—has become an accepted method for the comparison of medical interventions and the guidance of decisions on the most efficient use of health care resources.14 Therefore, we conducted a comprehensive economic analysis of the cost-effectiveness of using the IBS for platelets for AP and PC versus untreated AP and PC in the United States in patient populations in which platelets are commonly transfused.

MATERIALS AND METHODS

Model Overview

All data used in this analysis were summarized from existing published sources (primarily indexed in MEDLINE) and data on file at Baxter Healthcare Corporation (Chicago, Illinois) and Cerus Corporation (Concord, California). A literature-based decision-analytic model was developed to assess the economic costs and clinical outcomes associated with the use of AP and PC treated with the IBS for platelets (AP + IBS and PC + IBS). The current analysis expanded on the previ-
ously published decision-analytic model developed by Lopez-Plaza et al.\textsuperscript{15} in which the incremental cost (dollars/quality-adjusted life-year [QALY]) associated with the use of AP versus PC was evaluated. Similarly, this study simulated the possible transfusion-related events and outcomes in the patient populations that account for most platelet use in the United States. Specifically, the 2000 Healthcare Cost and Utilization Project (HCUP) data\textsuperscript{16} and other sources\textsuperscript{17} suggest that hematology/oncology, cardiovascular, and orthopedic treatment procedures or surgeries account for \textasciitilde76\% of the total platelet use in the United States. Therefore, patients undergoing hematopoietic progenitor cell transplant (HPCT) for acute lymphocytic leukemia (ALL) and non-Hodgkin's lymphoma (NHL), patients undergoing coronary artery bypass graft (CABG), and patients undergoing a hip arthroplasty were chosen as representative of patients who commonly receive platelet transfusions.\textsuperscript{17,18} Correspondingly, 4 reference patients were selected to represent the populations of all patients undergoing each procedure in the United States as reported in the 2000 HCUP\textsuperscript{16}: (1) a 10-year-old boy undergoing HPCT for ALL (similar to the patient population included in the HCUP [60\% male; mean age, 9 years]); (2) a 50-year-old man undergoing HPCT for NHL (similar to the patient population included in the HCUP [63\% male; mean age, 45 years]); (3) a 60-year-old man undergoing CABG (similar to the patient population included in the HCUP [71\% male; mean age, 64 years]); and (4) a 70-year-old woman undergoing a hip arthroplasty (similar to the patient population included in the HCUP [64\% female; mean age, 65 years]) (Table I).\textsuperscript{15,19–23}

A decision tree (Figure 1) was constructed for patients receiving AP + IBS versus AP without IBS. An identical decision tree was constructed for analysis of PC + IBS versus PC without IBS. The baseline model included the current risks of infection with HIV, HCV, HBV, HTLV-1, or bacterial agents for each platelet-donor exposure. The model simulated subsequent transfusion-related events and

| Table I. Excess annual mortality rates and quality-adjusted life-year (QALY) weights of underlying indications in the United States.\textsuperscript{15,19–23} |
|---------------------------------|-----------------|-----------------|-----------------|
| Indication                     | Year 1\textsuperscript{*} | Subsequent Years |
|                                | Mortality | QALY Weight | Mortality | QALY Weight |
| Pediatric ALL                  | 0.06      | 0.75         | 0.00      | 0.95        |
| NHL                             | 0.53      | 0.75         | 0.05      | 0.95        |
| CABG                            | 0.03      | 0.90         | 0.03      | 0.95        |
| Hip arthroplasty                | 0.00      | 0.95         | 0.00      | 0.95        |

\textit{ALL = acute lymphocytic leukemia; NHL = non-Hodgkin's lymphoma; CABG = coronary artery bypass graft.}

\textsuperscript{*}\textit{For pediatric ALL, years 1 to 3.}
Figure 1. Simplified illustration of decision tree for pathogen inactivation in patients undergoing platelet transfusion. ARC = AIDS-related complex; AP = single-donor apheresis platelets; HCV = hepatitis C virus; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HTLV-1 = human T-cell lymphotropic virus type 1; ATL = adult T-cell lymphoma; HAM = HTLV-I-associated myelopathy; TRS = transfusion-related sepsis; AP + IBS = pathogen-inactivated AP via the Intercept Blood System (trademark of Baxter Healthcare Corporation, Chicago, Illinois, and Cerus Corporation, Concord, California); [+] = repetition of subtree (as shown for AP).

outcomes, as well as events that would occur naturally; patients may experience morbidity and mortality due to several causes (eg, their underlying disease, transfusion-related complications, general mortality of populations of same age and sex).

Clinical outcomes resulting from underlying disease and transfusion-related complications were assigned a treatment cost and utility. Life expectancy estimates were calculated using the declining exponential approximation of life expectancy method\textsuperscript{24,25} and took into consideration competing mortality from
disease-specific and naturally occurring causes. The excess annual mortality rates and QALY weights (utility) for the study populations are presented in Table I.

The direct medical costs attributable to the use of AP + IBS and PC + IBS (as well as the present value of future costs attributable to treating transfusion-related complications) were incorporated in the baseline model. No indirect costs (eg, work productivity losses) were considered. Projected economic costs and health benefits in future years were discounted at 3% per annum, consistent with current practice.

The model then estimated the incremental cost and health benefit (ie, QALY) of using AP + IBS and PC + IBS versus untreated AP and PC, respectively. The incremental cost-effectiveness ratio (ICER) was then calculated as \( \frac{\text{cost}_{\text{AP+IBS}} - \text{cost}_{\text{AP}}} {\text{QALY}_{\text{AP+IBS}} - \text{QALY}_{\text{AP}}} \), representing (in this case) the incremental cost per QALY gained of using AP + IBS versus untreated AP.

### Table II. Risks for acquiring transfusion-transmitted pathogens and associated outcomes in the United States.

| Variable                                           | Baseline Value | Range                  |
|-----------------------------------------------------|----------------|------------------------|
| **Virus transmission risk per unit** \((1/X)\)       |                |                        |
| HIV\(^3\)                                           | 1,738,599      | 869,299–2,607,898\(^\dagger\) |
| HCV\(^3\)                                           | 1,575,733      | 787,866–2,363,599\(^\dagger\) |
| IBD\(^3\)                                           | 166,938        | 83,469–250,407\(^\dagger\) |
| HTLV-1\(^3\)                                        | 2,437,296      | 1,218,648–3,655,944\(^\dagger\) |
| **Deaths per million due to bacterial contamination** |                |                        |
| AP                                                  |                |                        |
| Without bacterial testing\(^6–8\)                   | 10             | 2–15                   |
| With bacterial testing\(^6–8\)                      | 1              | 0.1–2                  |
| PC\(^6–8\)                                          | 17             | 2–62                   |
| **Probability of disease outcome given transfusion event** |        |                        |
| ARC/AIDS\(^15\)                                     | 1.00           | NA                     |
| HCV/HBV                                             |                |                        |
| Chronic HCV\(^28,29\)                               | 0.850          | 0.690–0.880            |
| Chronic HBV\(^30,31\)                               | 0.100          | 0.020–0.200            |
| Cirrhosis\(^32–34\)                                 | 0.200          | 0.050–0.350            |
| HCC\(^29,35,36\)                                    | 0.050          | 0.010–0.200            |
| Fulminant infection\(^37,38\)                       | 0.010          | 0.001–0.010            |
| HTLV-1, ATL/HAM\(^15,39,40\)                        | 0.040          | 0.020–0.060\(^\dagger\) |

\(\text{HCV} = \text{hepatitis C virus}; \text{HBV} = \text{hepatitis B virus}; \text{HTLV-1} = \text{human T-cell lymphotropic virus type 1}; \text{AP} = \text{single-donor apheresis platelets}; \text{PC} = \text{random-donor pooled platelet concentrates}; \text{ARC} = \text{AIDS-related complex}; \text{HCC} = \text{hepatocellular carcinoma}; \text{ATL} = \text{adult T-cell lymphoma}; \text{HAM} = \text{HTLV-1–associated myelopathy}.\)

\(^*\)Weighed by 0.228 for repeat donors and 0.772 for first-time donors.

\(^\dagger\)\(\pm 50\%\) of baseline value.
The risks for acquiring transfusion-transmitted pathogens were derived from published data (Table II). For baseline values, the weighted mean risks for first-time donors and repeat donors were used. A recent study stated that the viral transmission risks from first-time donors were ~2 times greater than those from repeat donors. In addition, it was estimated that 22.8% of donations were from first-time donors. Therefore, the risks reported in that study were weighted by 0.228 and 0.772, respectively (Table II).

The subsequent outcome of transfusion-acquired HIV infection was AIDS-related complex, with a time to symptom onset of 5 years. Transfusion-acquired HCV or HBV outcomes were categorized into 4 groups: chronic hepatitis, cirrhosis, hepatocellular carcinoma (HCC), and fulminant hepatitis. Chronic hepatitis and fulminant hepatitis were assumed to occur in the year that transfusion was received. Cirrhosis and HCC onset were assumed to occur 15 years after transfusion. Adult T-cell leukemia/lymphoma or HTLV-I-associated myelopathy was the subsequent outcome of transfusion-acquired HTLV-I, with a time to symptom onset of 3 years. Probabilities of developing the above disease outcomes were estimated from the literature (Table II) as were the quality-of-life impact and mortality estimates attributable to the subsequent outcomes of transfusion-acquired sequelae (Table III).

The cumulative death rate was used to reflect the impact of bacterial contamination. Several studies have reported the death rates per million due to bacteria-contaminated blood transfusion. The death rates per million for bacterial contamination were calculated as a weighted mean by sample size, which were 10 per million for AP and 17 per million for PC (Table II). The BaCon study was excluded from these calculations because its risk underestimation was well recognized and its large sample size would bias the weighted mean. However, its data were used as the low bound in the sensitivity analysis to generate the most conservative estimate (2 deaths per million for both AP and PC). The data from a study from Johns Hopkins served as the high bound in the sensitivity analysis (15 and 62 deaths per million for AP and PC, respectively).

We expect the planned introduction of bacterial screening for AP in the United States in the near future to reduce the risk of bacterial contamination and TRS mortality. An alternative baseline scenario was developed that assumed that bacterial screening was widely used for AP and replaced by the IBS. Bacterial testing was assumed to cost $30 per dose of platelets and reduced mortality from bacterial contamination by 90% (ie, 1 death per million remained) with a range of 80% to 99% (ie, 0.1–2 deaths per million remained) for AP.
Table III. Excess annual mortality rates and quality-adjusted life-year (QALY) weights attributable to the subsequent outcomes of transfusion-related sequelae in the United States.

| Variable                              | Baseline Value | Range       |
|---------------------------------------|----------------|-------------|
| Annual mortality                      |                |             |
| ARC/AIDS\(^{15}\)                     | 0.10           | 0.05–0.15\(^{*}\) |
| HCV/HBV                               |                |             |
| Chronic infection\(^{29,41}\)         | 0.02\(^{†}\)   | 0.00–0.04\(^{*}\) |
| Cirrhosis\(^{31}\)                    | 0.20\(^{†}\)   | 0.15–0.25   |
| HCC\(^{42–44}\)                       | 0.80           | 0.33–1.00   |
| Fulminant infection\(^{38}\)          | 1.00           | N/A         |
| HTLV-I, ATL/HAM\(^{15}\)             | 0.10           | 0.05–0.15\(^{*}\) |
| QALY weights                          |                |             |
| HIV/AIDS\(^{45}\)                     | 0.76           | 0.60–1.00   |
| HCV/HBV                               |                |             |
| Chronic infection\(^{42–44,46}\)      | 0.88           | 0.60–1.00   |
| Cirrhosis\(^{34,42}\)                | 0.80           | 0.30–0.90   |
| HCC\(^{42–44}\)                       | 0.25           | 0.02–0.50   |
| Fulminant infection\(^{15}\)          | 0.00           | N/A         |
| HTLV-I, ATL/HAM\(^{15,47}\)          | 0.75           | 0.75–0.98   |

ARC = AIDS-related complex; HCV = hepatitis C virus; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HTLV-I = human T-cell lymphotropic virus type I; ATL = adult T-cell lymphoma; HAM = HTLV-I–associated myelopathy.

\(^{*}\)±50% of baseline value.

\(^{†}\)Midpoint of range.

Cost Parameters

Cost parameters were valued in year-2001 US dollars (Table IV).\(^{15,30,34,42–44,48–52}\) The health care component of the US Consumer Price Index was used to update costs calculated in previous years. Health care resource utilization cost components included the costs of AP and PC, pathogen inactivation treatment using the IBS for platelets, and the annual cost of treatment for transfusion-related sequelae. PC use assumed a pool of 6 random-donor units (based on a reported range of 4–10 units).\(^{53,54}\)

Sensitivity Analyses

Univariate scenario and multivariate sensitivity analyses were conducted to determine the robustness of the model results, to identify the variables that contributed the most to the model results, and to identify important model uncertainties. Univariate analysis, in which model variables were varied one by one, was conducted for the transfusion-transmission risk, the cost of treatment
Table IV. Cost parameter values (in year-2001 US $) for single-donor apheresis platelets (AP), random-donor pooled platelet concentrate (PC), pathogen inactivation, and treatment of transfusion-related sequelae in the United States.

| Parameter                                      | Cost  | Range          |
|------------------------------------------------|-------|----------------|
| Platelet cost                                  |       |                |
| PC (6-unit PC)                                 | 294   | 294–852        |
| AP                                             | 469   | 469–595        |
| Pathogen inactivation cost per unit*           | 100†  | 75–125‡        |
| Annual cost of treating transfusion-related sequelae |       |                |
| ARC/AIDS                                       | 45,776| 24,142–77,555  |
| HCV or HBV                                     |       |                |
| Chronic infection                              | 1,228 | 359–2,327      |
| Cirrhosis                                      | 11,627| 293–34,882     |
| HCC                                            | 16,245| 5,814–33,757   |
| Fulminant infection                            | 17,412| 8,706–26,118‡  |
| HTLV-1, ATL/HAM                                | 12,926| 6,463–75,852   |
| Hospitalization for TRS                        | 6,408 | 3,204–9,611§   |

ARC = AIDS-related complex; HCV = hepatitis C virus; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HTLV-1 = human T-cell lymphotropic virus type 1; ATL = adult T-cell lymphoma; HAM = HTLV-1-associated myelopathy; TRS = transfusion-related sepsis.

*Estimated cost based on data from Baxter Healthcare Corporation (Chicago, Illinois).
†For bacterially screened AP, the incremental cost was $70 ± 25%.
‡±25% of baseline value.
§±50% of baseline.

for transfusion-related sequelae, the cost of IBS, and the probability of disease outcomes.

In addition, the impact of eliminating the need for gamma irradiation was assessed. Gamma irradiation, a lymphocyte inactivation method for red blood cells and platelets, is commonly used to reduce the risk of graft-versus-host disease (GVHD). GVHD occurs when viable lymphocytes in transfused blood or blood components engraft, multiply, and react against the tissues of the recipient. Because the IBS for platelets targets DNA and RNA, it inactivates lymphocytes, potentially eliminating the need for gamma irradiation. To assess this impact, a scenario in which gamma irradiation (process cost, $38 to the hospital) was no longer required when using AP + IBS and PC + IBS was included in a sensitivity analysis.

Another potential benefit of pathogen inactivation via the IBS for platelets is the ability to reduce the risk of transmission of emerging pathogens. New pathogens continue to be discovered every 2 to 5 years, with >40 new diseases/
microorganisms identified in the last 30 years, including HIV/AIDS and HCV.\textsuperscript{58} For every new pathogen discovered, there is a time lag between pathogen discovery and the widespread availability of an effective test. Even if an effective test is developed, there exists the possibility that the pathogen may not be detected (eg, because of small pathogen-load counts). In the case of HCV, \textasciitilde 300,000 Americans were infected via blood transfusions (primarily before 1990) before the approval of the first HCV blood test.\textsuperscript{59} To further assess the impact of using AP + IBS and PC + IBS, a hypothetical scenario involving HCV-like pathogens was incorporated into sensitivity analyses. The risk for acquiring these emerging pathogens was assumed to be 1 per 3300 units, similar to that of HCV when first discovered.\textsuperscript{60} Subsequent outcomes and treatment costs were based on that of HCV in the baseline models.

An additional consideration was that the use of the IBS for platelets could increase platelet use because of losses from the pathogen inactivation process and reduction of platelet recovery.\textsuperscript{61,62} To assess this impact, the baseline model was assessed under the scenario in which platelet use was increased by 20%, with a range of 10% to 30% tested in the sensitivity analysis.

Finally, a multivariate sensitivity analysis on all variables provided with a range in Tables II to IV was conducted via Monte Carlo simulation (probabilistic sensitivity analysis). This entailed conducting 10,000 iterations of the model using (for each iteration) a random set of model parameter values selected from the assumed parameter distributions, which were based on the range of values found in the literature (see Tables II–IV). When parameter distributions were unavailable, triangular distributions were used, where the presumed likeliest value (ie, the baseline value) fell between the minimum and maximum values, assumed to be \pm 50\% from baseline. The 10,000 iterations of expected costs and outcomes were used to calculate ICERs, from which a cost-effectiveness acceptability curve\textsuperscript{63} was generated to illustrate the confidence with which it may be inferred that use of AP + IBS and PC + IBS would be cost-effective over a range of thresholds of acceptability.

**RESULTS**

**Baseline Analysis**

The baseline results in year-2001 US dollars are presented in Table V (for AP) and Table VI (for PC). They show that, for all 4 patient populations, IBS treatment was more cost-effective for PC ($457,586–$1,816,060) than AP ($1,308,833–$4,451,650 in baseline scenario 1 and $4,759,401–$22,968,066 in baseline scenario 2). IBS was also more cost-effective in the pediatric patient population studied versus the other 3 adult patient populations for both AP and PC.
Table V. Incremental cost-effectiveness ratio (cost per quality-adjusted life-year) of using single-donor apheresis platelets (AP) treated with the Intercept Blood System* (IBS) versus untreated AP in the United States in year-2001 US $.

| Analysis | Pediatric ALL | Hip Arthroplasty | CABG | NHL |
|----------|---------------|------------------|------|-----|
| Baseline scenario 1: IBS-treated AP versus untreated AP without bacterial testing | 1,308,833 | 2,225,819 | 2,644,880 | 4,451,650 |
| Baseline scenario 2: IBS-treated AP versus untreated AP with bacterial testing† | 4,759,401 | 10,697,249 | 13,408,731 | 22,968,066 |
| Sensitivity analysis 1: baseline + low fatality from bacterial contamination† | | | | |
| Baseline scenario 1 | 4,120,098 | 8,323,879 | 10,201,154 | 17,341,912 |
| Baseline scenario 2 | 7,105,810 | 20,128,437 | 26,803,402 | 46,905,925 |
| Sensitivity analysis 2: baseline + high fatality from bacterial contamination§ | | | | |
| Baseline scenario 1 | 917,439 | 1,526,577 | 1,807,689 | 3,039,215 |
| Baseline scenario 2 | 3,481,838 | 7,034,690 | 8,621,330 | 14,656,642 |
| Sensitivity analysis 3: baseline + 30% increased platelet utilization | | | | |
| Baseline scenario 1 | 1,858,322 | 3,160,073 | 3,754,950 | 6,319,736 |
| Baseline scenario 2 | 6,998,621 | 15,728,771 | 19,715,079 | 33,768,313 |
| Sensitivity analysis 4: baseline + emergent HCV-like virus benefit | | | | |
| Baseline scenario 1 | 238,901 | 663,511 | 876,334 | 1,527,664 |
| Baseline scenario 2 | 234,807 | 743,993 | 1,024,007 | 1,811,930 |
| Sensitivity analysis 5: baseline + high fatality from bacterial contamination§ + gamma irradiation benefit (for ALL and NHL) + emergent HCV-like virus | | | | |
| Baseline scenario 1 | 177,695 | 583,456 | 759,353 | 1,058,127 |
| Baseline scenario 2 | 176,572 | 550,386 | 982,161 | 1,330,703 |

ALL = acute lymphocytic leukemia; CABG = coronary artery bypass graft; NHL = non-Hodgkin's lymphoma; HCV = hepatitis C virus.
*Trademark of Baxter Healthcare Corporation (Chicago, Illinois) and Cerus Corporation (Concord, California).
†1 death per 1 million.
‡2 and 0.1 deaths per 1 million for baseline scenarios 1 and 2, respectively.
§15 and 2 deaths per 1 million for baseline scenarios 1 and 2, respectively.
Table VI. Incremental cost-effectiveness ratio (cost per quality-adjusted life-year) of using the random-donor pooled platelet concentrate (PC) treated with the Intercept Blood System* (IBS) compared with untreated PC in the United States in year-2001 US $.

| Analysis                                                                 | Pediatric ALL | Hip Arthroplasty | CABG       | NHL       |
|--------------------------------------------------------------------------|--------------|-----------------|------------|-----------|
| Baseline analysis                                                        | 457,586      | 881,424         | 1,070,533  | 1,816,060 |
| Sensitivity analysis 1: baseline + low fatality from bacterial contamination† | 1,013,670    | 2,639,617       | 3,431,576  | 5,957,993 |
| Sensitivity analysis 2: baseline + high fatality from bacterial contamination‡ | 172,743      | 293,597         | 348,918    | 587,798   |
| Sensitivity analysis 3: baseline + 30% increased platelet utilization     | 620,693      | 1,195,069       | 1,451,270  | 2,461,231 |
| Sensitivity analysis 4: baseline + emergent HCV-like virus benefit        | 34,845       | 109,412         | 149,861    | 266,593   |
| Sensitivity analysis 5: baseline + high fatality from bacterial contamination‡ + gamma irradiation benefit (for ALL and NHL) + emergent HCV-like virus | 22,888       | 86,992          | 115,445    | 153,564   |

ALL = acute lymphocytic leukemia; CABG = coronary artery bypass graft; NHL = non-Hodgkin’s lymphoma; HCV = hepatitis C virus.
*Trademark of Baxter Healthcare Corporation (Chicago, Illinois) and Cerus Corporation (Concord, California).
†2 deaths per 1 million.
‡62 deaths per 1 million.

Sensitivity Analyses

Univariate sensitivity analyses indicated that the model results were sensitive to individual changes in the value of several parameters. Specifically, the following parameters were most likely to affect the model results: (1) mortality due to bacterial contamination; (2) IBS effect on platelet utilization; and (3) the inclusion of potential benefits (ie, gamma irradiation and/or emergent HCV-like virus).

Corresponding ICERs from different scenarios are presented in Table V and Table VI. In contrast with these findings, changes in the IBS price and transmission risks of HIV, HBV, HCV, and HTLV-1 within the ranges tested did not significantly alter the model results.

The ICERs were highly sensitive to the death rate due to bacterial contamination. When the death rate increased from 2 deaths per million for both AP
and PC to 15 deaths and 62 deaths per million for AP and PC, respectively, the incremental cost per QALY decreased from $4,120,098 to $917,439 for AP + IBS versus AP and from $1,013,670 to $172,743 for PC + IBS versus PC among pediatric ALL patients. When the mortality rate increased from 0.1 death per million to 2 deaths per million for bacterially screened AP, the incremental cost per QALY decreased from $7,105,810 to $3,481,838 for AP + IBS versus AP among pediatric ALL patients. Similar trends were found in other patient populations.

Increased platelet use due to IBS treatment also increased the ICERs. The ICERs increased ~45% when the platelet yield reduction rate was raised from 20% to 30% for both AP and PC in all patient populations. Conversely, the ratio decreased by ~33% when the platelet yield reduction rate was decreased to 10%.

Elimination of the need for gamma irradiation reduced the ICERs by ~20% to 25% for both AP and PC in ALL and NHL patients. This scenario was not assessed in patients undergoing CABG and hip arthroplasty surgery because, in our experience, these patients do not typically require irradiated blood components.

When an emerging, highly prevalent HCV-like pathogen was introduced into the model, the costs per QALY of AP + IBS and PC + IBS decreased dramatically in all 4 patient populations. For AP + IBS, the ICERs declined to a range of $238,901 to $1,527,664 per QALY using baseline scenario 1 and a range of $234,807 to $1,811,930 per QALY using baseline scenario 2. For PC + IBS, the ICERs decreased to a range of $34,845 to $266,593 per QALY.

As expected, consideration of the combined scenarios in which the high bound of death rates from bacterial contamination was used, gamma irradiation was no longer required, and an emerging HCV-like pathogen was introduced, resulting in dramatically lower ICERs compared with the baseline scenarios. The maximum observed ICER was less than $1,331,000 per QALY for AP + IBS and less than $154,000 per QALY for PC + IBS.

The probabilistic sensitivity analysis indicated that the results were sensitive to simultaneous changes to the multiple parameters listed (with a range) in Tables II to IV. For instance, in pediatric ALL patients, results of Monte Carlo simulations indicated that the ICER of AP + IBS versus untreated AP was less than $2.0 million (without bacterial testing)/$5.7 million (with bacterial testing) in 50% of model runs, and less than $4.1 million (without bacterial testing)/$8.9 million (with bacterial testing) in 95% of model runs. For the other 3 patient populations, the ICERs of AP + IBS versus untreated AP were less than $4.4 million/$14.2 million (hip arthroplasty), less than $4.9 million/$18.5 million (CABG), and less than $8.3 million/$32.1 million (NHL) in 50% of model runs, and less than $8.5/$22.0 million (hip arthroplasty), $9.4/$28.9 million (CABG), and $15.8/$49.9 million (NHL) in 95% of model runs.
DISCUSSION
The current analysis provided a comprehensive economic assessment of APs and PCs treated with the IBS for platelets. The decision-analytic model accounts for the morbidity and mortality associated with the patient's underlying condition, as well as that of transfusion-related complications. The model used the most recently published pathogen-transmission risks, subsequent transfusion-related outcomes, and treatment costs to assess the health benefit and cost-effectiveness of the IBS for platelets in patients who commonly receive platelet transfusions.

In this model, we observed that the cost of transfusion of AP + IBS versus untreated AP ranged from $1,308,833 (pediatric ALL) to $4,451,650 (NHL) for each QALY saved. For bacterially screened AP, the reduced mortality rate from bacterial contamination makes the incremental cost per QALY of IBS treatment in excess of $4 million for all patient populations at baseline. Corresponding figures for the transfusion of PC + IBS versus untreated PCs ranged from $457,586 (pediatric ALL) to $1,816,060 (NHL). Although seemingly high compared with the threshold ratios commonly used in other fields of medicine, such as $50,000 per QALY, these ICERs are comparable to previously reported cost-effectiveness findings of accepted blood safety interventions. For instance, a recent study by Jackson et al. showed that the ICERs of whole-blood NAT for HIV, HCV, and HBV ranged from $4.7 to $11.2 million per QALY saved. Stone et al. also found that blood safety interventions had a median ICER of $355,000 per QALY, with values ranging from cost-saving to $8.7 million per QALY. A graphic summary of the results of published cost-effectiveness analyses of safety interventions (Figure 2) indicated that ICERs for blood safety and injury prevention measures were dominated by ratios higher than $100,000 per QALY. These findings suggest that the IBS is associated with ICERs comparable with those of other existing or proposed blood safety interventions that are highly valued by the public and policy makers. The risk of transfusion-transmitted infections due to currently screened pathogens is relatively small, but the continued addition of new tests such as NAT suggests that safety is still paramount in policy decision-making processes. Thus, higher cost-effectiveness thresholds may apply in the evaluation of new blood safety technologies.

The results of the present analysis indicated that the IBS for platelets was relatively more cost-effective for pediatric ALL patients and orthopedic patients, followed by CABG and NHL patients. Overall, this finding reflected the favorable short-term prognosis of pediatric ALL and orthopedic patients, because mortality and quality of life after treatment were relatively similar to those expected for normal populations. The anticipated life expectancy of pediatric ALL patients was also greater due to their younger age at the time of transfusion. In contrast, the NHL and CABG patient populations were associated with relatively higher first-year posttreatment mortality rates, reducing the potential benefits of avoidance of transfusion-related infections.
Figure 2. Illustration of incremental cost-effectiveness ratios (ICERs) for implemented blood safety interventions and other injury prevention measures, shown as US $ per quality-adjusted life-year gained. NAT = nucleic acid amplification technology; AP = single-donor apheresis platelets; IBS = Intercept Blood System (trademark of Baxter Healthcare Corporation, Chicago, Illinois, and Cerus Corporation, Concord, California); ALL = acute lymphocytic leukemia; HCV = hepatitis C virus; HBV = hepatitis B virus; CABG = coronary artery bypass graft; NHL = non-Hodgkin’s lymphoma; ELISA = enzyme-linked immunosorbent assay.
Sensitivity analysis indicated that the model results were not significantly affected by changes in viral-transmission risks for which testing is currently performed. The benefits of the IBS for platelets were driven by TRS mortality due to bacterial contamination of platelets. Currently, bacterial contamination remains the most frequent infectious complication associated with platelet transfusions.

Although the adoption of bacterial testing in the United States in the near future is expected to reduce the risk of bacterial contamination and TRS mortality, residual risks will remain due to the limitations of bacterial testing systems. In such circumstances, the benefit of the IBS would actually be substantially reduced (as shown in the baseline scenario 2). However, the concurrent use of pathogen inactivation and bacterial testing is very unlikely. A generalized use of the IBS would probably omit the need for bacterial testing.

The mortality from bacterial contamination was directly modeled in the current analysis without consideration for nonfatal outcomes. The rationale for such an approach is as follows: (1) Varying clinical definitions of transfusion reactions have led to a number of differing reports of TRS incidence, such as the incidence of sepsis, mild/severe septic reactions, bacterial contamination, bacteria-related events, transfusion reactions, and so on, all of which lack a clear consensus of the true incidence—however, the cumulative mortality rate per million units has been consistently used in the literature to estimate the impact of TRS; (2) rates for nonfatal reactions are often underestimated because of underrecognition and underreporting; (3) the economic impact of septic reactions (mild or severe) due to bacterial contamination is minimal and may be neglected due to the rare occurrence; and (4) focusing on the critical effect of TRS—patient mortality—may simplify, as well as clarify, the model.

The mortality rate due to bacterial contamination has been reported in several well-known studies. A surveillance study in the United States found cumulative death rates of 2.2 and 1.9 per million for AP and PC, respectively, based on data for the years 1998 to 2000. However, as with other surveillance studies (eg, US Food and Drug Administration surveillance for bacterial safety), the fatality and incidence rates were underestimated because of limitations of surveillance study methodology. A study conducted in France with a matched case-control study design reported that the cumulative death rates with PC and AP were 0.0 (95% CI, 0.0–35.8) and 7.1 (95% CI, 0.8–25.6) per million. A study at Johns Hopkins revealed that the cumulative death rates during the 12-year period (1987–1998) were 15 per million for AP and 62 per million for PC. These rates were much higher than those from surveillance data and may reflect the more aggressive ability of hospital-based studies to detect and report cases. Considering the limitations and strengths of each study, the death-per-million rates for bacterial contamination were conservatively calculated in our study as a weighted average by sample size: 10 per million for AP and 17 per million for PC. The
BaCon study was excluded from these calculations because its underestimation was well recognized and the large sample size would bias the weighted average.

The IBS for platelets was designed to reduce the risk of transmission of known pathogens (eg, HIV, HCV, HBV, HTLV-1, bacterial agents) for the >4 million units of platelets transfused annually in the United States, Europe, and Japan (ie, ~2.3 HIV, ~2.5 HCV, ~24.0 HBV, ~1.6 HTLV-1 infections, and ~68 deaths due to bacterial contamination could be avoided). However, the system also has the potential to reduce the risks associated with emerging pathogens for which no donor screening strategy or laboratory test currently exists. Therefore, this study conservatively adopted a hypothetical HCV-like pathogen to assess the potential benefit of the IBS in preventive reduction of the infection risk from emerging pathogens. Unlike HIV-like viruses, most HCV infections do not result in severe clinical illness and remain asymptomatic. To generate conservative estimates, this virus was selected to mimic an emerging virus scenario. The results from the sensitivity analysis indicated that the IBS would be much more cost-effective in all 4 patient populations with this potential benefit included in the model. As expected, a scenario in which multiple new pathogens were encountered would further improve the cost-effectiveness of the IBS.

One of the most important trends in health care is the increasing emphasis on disease prevention. The potential of the IBS to prevent the transmission of emerging pathogens such as the causative agent of severe acute respiratory syndrome and West Nile virus may increase the safety of platelet transfusions. The IBS may also help avoid the otherwise inevitable addition of new screening tests. This study was intended to generate conservative results. For example, the study did not include the potential benefit of the IBS in extending the shelf-life of platelet concentrates, although it has been reported that, in principle, pathogen inactivation may extend the storage time of platelet concentrates to 7 days (from the current 5 days). In addition, no indirect costs were considered attributable to worker productivity losses due to premature death and litigation costs stemming from pathogen transmission and sequelae. Inclusion of these potential benefits would result in more favorable results for both AP + IBS and PC + IBS.

A critical assumption of the current analysis was that the IBS for platelets was 100% effective in the prevention of transmission of the pathogen used in the model and was not associated with adverse health effects. Clinical trials in the United States and Europe have assessed the efficacy and safety of the IBS for platelets, and no excess treatment-related adverse events have been detected in patients receiving treated platelet components. However, inherent to the assumed benefit of use of platelets treated with the pathogen inactivation process is a level of uncertainty, and any benefit gained from the use of pathogen-inactivated platelets may be offset by the incidence of an unanticipated adverse event or any other treatment-related hazard.
CONCLUSIONS
The cost-effectiveness of pathogen inactivation via the IBS for platelets is comparable to that of other accepted blood safety interventions (eg, NAT testing, HIV p24 antigen testing, solvent-detergent treatment). The major advantages of the IBS are the prevention of virus transmission, bacterial contamination, and emerging pathogens, and perhaps the avoidance of future screening tests as well. Blood banks, hospitals, and other institutions that administer platelet transfusions could consider the IBS for platelets a desirable strategy to increase the safety of platelet transfusions and a potential insurance against the threat of emerging pathogens.

ACKNOWLEDGMENT
This research was funded by Baxter Healthcare Corporation, Transfusion Therapies (Madrid, Spain).

REFERENCES
1. Dodd RY. The safety of the blood supply: Current concepts. In: Hillyer CD, ed. The Safety of the Blood Supply: The Fenwal Monograph Series. Deerfield, Ill: Baxter Healthcare Corporation; 199; l-l 7.
2. Dow BC, Peterkin MA, Green RH, Cameron SO. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang. 2001;81:140. Letter.
3. Dodd RY, Notari EP Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979.
4. Schuttler CG, Caspari G, Jursch CA, et al. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet. 2000;355:41–42. Letter.
5. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: Incidence, significance, and prevention. Semin Hematol. 2001;38(Suppl 11):20–26.
6. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493–1499.
7. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857–861.
8. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion-associated bacterial contamination: Results of the French BACTHEM Case-Control Study. Transfusion. 2001;41:862–872.
9. Barbara J. The rationale for pathogen inactivation treatment of platelet components—introduction. Semin Hematol. 2001;38(Suppl 11):1–3.
10. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140–3147.
11. Knutson E, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209–216.

12. Rios J, Hambleton J, Viele M, et al. Helinx treated RBC transfusions are well tolerated and show comparable recovery and survival to control RBCs. Presented at: 54th Annual Meeting of the American Association of Blood Banks; October 13–17, 2001; San Antonio, Tex.

13. deAlarcon P, Benjamin R, Shopnick R, et al. Hemostatic response in congenital coagulation factor-deficient patients transfused with fresh frozen plasma (FFP) prepared by Helinx pathogen inactivation technology—The Step CC Trials. Presented at: 54th Annual Meeting of the American Association of Blood Banks; October 13–17, 2001; San Antonio, Tex.

14. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1997.

15. Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion. 1999;39:925–932.

16. HCUPnet. Healthcare Cost and Utilization Project Web site. Available at: http://hcup.ahrq.gov/HCUPnet.asp. Accessed April 10, 2003.

17. Blood Products Usage Summary 2002. Rockville, Md: InforMedix Marketing Research, Inc; 2002.

18. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: Utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251–256.

19. Garellick G, Malchau H, Herberts P, et al. Life expectancy and cost utility after total hip replacement. Clin Orthop. 1998;346:141–151.

20. Dearborn JT, Harris WH. Postoperative mortality after total hip arthroplasty. An analysis of deaths after two thousand seven hundred and thirty-six procedures. J Bone Joint Surg Am. 1998;80:1291–1294.

21. Berg S, Steuber P, Poplack D. Clinical manifestations of acute lymphoblastic leukemia. In: Hoffman R, Benz E Jr, Shattil SJ, et al, eds. Hematology, Basic Principles and Practice. New York: Churchill Livingstone; 2000:1070–1078.

22. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257–4264.

23. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637.

24. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). 1. Validation of the method. Am J Med. 1982;73:883–888.

25. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 1982;73:889–897.

26. Brecher ME, Means N, Jere CS, et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: An analysis with 15 contaminating organisms. Transfusion. 2001;41:477–482.
27. Blood Products Advisory Committee 76th Meeting Minutes. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research; 2003.
28. Trivedi M. Newly diagnosed hepatitis C. Lack of symptoms doesn't mean lack of progression. Postgrad Med. 1997;102:95–98, 101.
29. Muir AJ. The natural history of hepatitis C viral infection. Semin Gastrointest Dis. 2000;11:54–61.
30. Birkmeyer JD, AuBuchon JP, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg. 1994;57:161–168.
31. National Center for Infectious Diseases. Viral hepatitis B. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/b/index.htm. Accessed January 8, 2003.
32. Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2000;95:1524–1530.
33. Theodore D, Fried MW. Natural history and disease manifestations of hepatitis C infection. Curr Top Microbiol Immunol. 2000;242:43–54.
34. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111:614–621.
35. Lam NP. Hepatitis C: Natural history, diagnosis, and management. Am J Health Syst Pharm. 1999;56:961-973.
36. Satoor S, Raufman JP. Treatment of hepatitis C. Clin Cornerstone. 2001;3:37–46.
37. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001:1721–1742.
38. Owens DK, Nease RF Jr. Occupational exposure to human immunodeficiency virus and hepatitis B virus: A comparative analysis of risk. Am J Med. 1992;92:503–512.
39. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332:719–724.
40. Roback JD, Hillyer CD. The role of leukocyte reduction in minimizing the risk of transfusion-transmission of cell-associated infectious agents and immunomodulation. In: Hillyer CD, ed. The Safety of the Blood Supply: The Fenwal Monograph Series. Deerfield, Ill: Baxter Healthcare Corporation; 1999:28–45.
41. Ohlen J, Liegl JM, Selmair H. Long-term prognosis of chronic B and C viral hepatitis [in German]. Leber Magen Darm. 1995;25:205–210.
42. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866–874.
43. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318–1324.
44. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855–865.

45. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res. 1999;8:471–480.

46. Patil R, Cotler SJ, Banaad-Omiotek G, et al. Physicians' preference values for hepatitis C health states and antiviral therapy: A survey. BMC Gastroenterol. 2001;1:6.

47. Stigum H, Magnus P, Samdal HH, Nord E. Human T-cell lymphotrophic virus testing of blood donors in Norway: A cost-effect model. Int J Epidemiol. 2000;29:1076–1084.

48. American Red Cross. Hospital Information: Reimbursement. Available at: http://www.redcrosslife.org/hospital/hos_reimbursement.asp. Accessed January 14, 2003.

49. Financial impact of technologies to improve blood safety. Testimony by America’s Blood Centers before Medicare Payment Advisory Commission. Available at: http://www.americasblood.org/index.cfm?fuseaction=Display.showPage&pageid=61. Accessed February 6, 2003.

50. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897–1904.

51. Aubuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion. 1997;37:45–51.

52. Hart AC, Richards B, eds. DRG Guidebook. 17th ed. Reston, Va: St. Anthony Publishing; 2000.

53. Solheim BG, Wesenberg F. Rational use of blood products. Eur J Cancer. 2001;37:2421–2425.

54. Zeger G, Williams CT, Shulman IA. Single donor platelets: Can we afford to use them? Can we afford not to use them? Transfus Sci. 1997;18:585–588.

55. Guidance for Industry: Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research; 2000.

56. The future use of pathogen-inactivated platelet concentrates. Vox Sang. 2003;85:54–66.

57. List of ambulatory payment classifications (APCs) with status indicators, relative weights, payment rates, and copayment amounts calendar year 2002. 66 Federal Register 44726 (2001).

58. Solberg CO. Microorganisms strike back—Infectious diseases during the last 50 years [in Norwegian]. Tidsskr Nor Laegeforen. 2001;121:3538–3543.

59. Hepatitis C: An emerging threat to public health. US Department of Health and Human Services Web site. Available at: www.hhs.gov/news/press/2001pres/01fshepatitisC.html. Accessed February 14, 2003.

60. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:369–373.
61. McCullough J, Vesole D, Benjamin RJ, et al. Pathogen inactivated platelets (plt) using Helinx technology (INTERCEPT plt) are hemostatically effective in thrombocytopenic patients (tcp plt): The SPRINT trial. Blood. 2001;98:450a. Abstract.
62. van Rhenen D, Gulliksson H, Pamphilon D, et al. S-59 (Helinx) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: Results of the EuroSPRITE phase 3 trial. Blood. 2000;96:823a. Abstract.
63. van Hout BA, Al MJ, Gordon GS, Rutten FE. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309-319.
64. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making. 2000;20:332-342.
65. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721-729.
66. Stone PW, Teutsch S, Chapman RH, et al. Cost-utility analyses of clinical preventive services. Published ratios, 1976-1997. Am J Prev Med. 2000;19:15-23.
67. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272:1210-1214.
68. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: Application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion. 2000;40:1182-1191.
69. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479-487.
70. Yeh JM, Botteman M, Pashos CL, et al. Economics of transfusion. Infusionsther Transfusionsmed. 2002;29:218-225.
71. Loubiere S, Rotily M, Durand-Zaleski I, et al. Adjunction of polymerase chain reaction in screening for hepatitis C virus RNA in blood donations: Misuse of the principle of caution. Hypotheses Debats. 2001;17:344-349.
72. Simmonds P, Kurtz J, Tedder RS. The UK blood transfusion service: Over a (patent) barrel? Lancet. 2002;359:1713-1714.
73. Grima DT, Marshall D, Weinstein M, et al. Cost-effectiveness of screening donated blood with minipool nucleic acid testing for hepb virus, hepatitisC virus, and HIV. Value Health. 2002;5:446. Abstract.
74. van Hulst M, de Wolf JT, Staginnus U, et al. Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sang. 2002;83:146-155.
75. Sibrowski W, Penner M, Kuhn P. Transfusion-induced virus infections: How great is the risk? [in German]. Infusionsther Transfusionsmed. 1993;20(Suppl 2):4-9.
76. Roth VR, Kuehnert MJ, Haley NR, et al. Evaluation of a reporting system for bacterial contamination of blood components in the United States. Transfusion. 2001;41:1486-1492.
77. Workshop on bacterial contamination of platelets—9/24/1999. US Food and Drug Administration Web site. Available at: http://www.fda.gov/cber/minutes/workshop-min.htm. Accessed November 21, 2002.
78. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion. 2000;40:1161–1164.
79. New data show that INTERCEPT Blood System inactivates virus in same viral family as SARS [press release]. Madrid, Spain: Baxter Healthcare Corporation; June 17, 2003.
80. Dupuis K, Alfonso R, Savoor A, et al. Helinx Technology, used in the Intercept Blood System, inactivates high titers of emerging insect-borne pathogens in platelets and red blood cells. Abstract presented at: VIII International Society of Blood Transfusion Regional European Congress; July 5–9, 2003; Istanbul, Turkey.

Address correspondence to: Ulf Staginnus, MS, Baxter Healthcare Corporation, SL, Transfusion Therapies, Parque Empresarial, San Fernando, Edificio Londres, 28830 Madrid, Spain. Email: ulf_staginnus@baxter.com